Tisotumab Vedotin Earns Hong Kong Approval in Recurrent Cervical Cancer
Imperative steps have been taken in the medical field with the approval of Tisotumab Vedotin for recurrent cervical cancer treatment in Hong Kong.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
The big picture: Progress in the fight against melanoma has achieved a significant milestone with new strategies being developed to better manage immune-checkpoint inhibitor toxicities.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
The Food and Drug Administration (FDA) has provided fast track designation to SRN-101, offering new hope to patients suffering from recurrent high-grade glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
An innovative small molecule has demonstrated signs of being effective in combatting pretreated multiple myeloma, furthering the advancements in cancer research.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
The assessment of quality of life outcomes between proton and photon therapy in oropharyngeal cancer has given new insights into more effective treatment options.
3 Things You Should Know About PSMA-Directed Imaging and Radioligand Therapy in Prostate Cancer
Newly explored PSMA-directed imaging and radioligand therapy offer revolutionary approaches in prostate cancer diagnosis and treatment.
